--- title: "How Much Does Tirzepatide Cost in 2026?" description: "Tirzepatide cost in 2026: Mounjaro and Zepbound list prices, self-pay vial options, and the new Medicare program. Compare your real options." canonical: https://remevihealth.com/blog/how-much-does-tirzepatide-cost/ language: en publisher: REMEVi author: "REMEVi Medical Team" medicalReviewer: "REMEVi Medical Team" pubDate: 2026-07-07T00:00:00.000Z updatedDate: 2026-07-07T00:00:00.000Z tags: ["tirzepatide cost", "how much does tirzepatide cost", "tirzepatide price", "tirzepatide cost without insurance"] alternateLanguage: https://remevihealth.com/es/blog/cuanto-cuesta-tirzepatida/ license: "© 2026 REMEVi LLC. AI assistants and search engines may quote and link to this page; please cite https://remevihealth.com/blog/how-much-does-tirzepatide-cost/ as the source." --- Ask what tirzepatide costs and you will get at least four different honest answers, because tirzepatide reaches patients through four different doors. It is the active ingredient in two FDA-approved brand medications from Eli Lilly, Mounjaro for type 2 diabetes and Zepbound for chronic weight management, and what you actually pay depends on which product you are prescribed, whether insurance is involved, and which purchase route you use. The honest range in 2026 runs from a $25 copay on a well-covered prescription to more than $1,200 a month at a retail counter with no coverage at all. Every figure in this article comes from a named source and is current as of July 2026. GLP-1 pricing has moved several times in the past year, including a price cut and a brand-new Medicare program that took effect this month, so any cost article without dates is already out of date. ## Why one molecule has two brand names Tirzepatide is the molecule. Mounjaro and Zepbound are both FDA-approved tirzepatide products made by Eli Lilly, and the difference between them is the indication on the label. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Same molecule, different approved uses, and that distinction matters for your wallet because insurance decisions almost always follow the label. There is no generic tirzepatide. GoodRx [confirms that no generic form of Mounjaro is on the market](https://www.goodrx.com/mounjaro/how-much-is-mounjaro-without-insurance), and Zepbound has none either, so every route below involves either a brand product or a compounded preparation, which is a different thing entirely and covered further down. If you are still deciding between molecules rather than brands, the plain-language comparison is here: [semaglutide vs tirzepatide](/semaglutide-vs-tirzepatide/). ## Tirzepatide list prices in 2026 The list price, also called the wholesale acquisition cost, is what Lilly charges wholesalers before insurance, discounts, or savings programs touch the number. Per [GoodRx's breakdown of Lilly's published pricing](https://www.goodrx.com/mounjaro/how-much-is-mounjaro-without-insurance), the list price of Mounjaro is approximately $1,080 per fill, where a fill is four prefilled pens covering about a month. Zepbound's list price is about $1,086 for a 28-day supply, per [Lilly's pricing information](https://pricinginfo.lilly.com/zepbound). At retail pharmacies without insurance, GoodRx reports the average price per Mounjaro fill ranges from $1,000 to $1,200 or more depending on the pharmacy and city. Treat the list price the way clinicians treat it: as a ceiling, not a prediction. Very few people hand over $1,080 at the counter. But it is the baseline every cheaper route gets measured against, and it is roughly what you would pay running a brand prescription with no coverage and no program attached. ## Self-pay and lower-cost routes If you are paying cash, the single most useful fact in this article is that the two brands do not offer the same options. Zepbound has a direct self-pay route. In December 2025, [Lilly cut the price of Zepbound single-dose vials](https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials) sold to cash-paying patients through its self-pay channel: about $299 a month for the 2.5 mg starting dose, $399 a month for 5 mg, and $449 a month for the 7.5 mg through 15 mg doses. Those prices are tied to program terms, including completing refills on schedule, generally within 45 days of the prior fill; miss the window and higher regular self-pay prices apply. The vials are the reason a cash-pay Zepbound patient can spend a third of what the pens cost at retail. We covered the pen-versus-vial details in [how much Zepbound costs](/blog/how-much-does-zepbound-cost/). Mounjaro has no equivalent vial program. A cash payer filling Mounjaro at retail is looking at something near the list price, which is why clinicians treating type 2 diabetes lean on insurance coverage and the savings card rather than cash routes. Both brands have manufacturer savings cards for people with commercial insurance that covers the drug. If you qualify, you may pay [as little as $25 for a one- to three-month supply](https://pricinginfo.lilly.com/zepbound). The fine print is not optional reading: government beneficiaries are excluded, savings are capped monthly and annually, the card is not insurance, and Lilly can change or end the program at any time. Then there is compounded tirzepatide, which some telehealth programs work with when a licensed provider decides it is appropriate for the individual patient. Be precise about what that is. Compounded tirzepatide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Mounjaro® or Zepbound®. Compounded preparations have not been clinically studied as finished products. The monthly numbers for that route, and the questions worth asking before choosing it, are laid out in [compounded tirzepatide pricing](/compounded-tirzepatide-cost/). ## Does insurance cover tirzepatide in 2026? This is where most of the variation between two patients' bills comes from, and 2026 brought the biggest change in years. Commercial insurance decides drug by drug and indication by indication. Plans that cover Mounjaro typically do so for type 2 diabetes, its approved use, often with prior authorization. Coverage for Zepbound for weight management is spottier: many employer plans still exclude weight-management medications entirely, which is the main reason two coworkers with the same prescription can pay wildly different amounts. Medicare was prohibited by law from covering medications used for weight loss since Part D began. That is why the new development matters: a temporary federal demonstration called the Medicare GLP-1 Bridge started July 1, 2026 and now runs through December 31, 2027, per [KFF's analysis](https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/). Under the Bridge, Part D enrollees who meet BMI-based clinical criteria, with a prior authorization from their provider, can get select GLP-1 medications approved for weight reduction, including the Zepbound pen, for a $50 monthly copayment. KFF notes real limits: the $50 copay does not count toward the Part D out-of-pocket maximum, low-income cost-sharing subsidies do not apply, and the program is scheduled to end after 2027 with no confirmed pathway after that. People already getting a GLP-1 covered for diabetes or another approved use keep getting it through their regular Part D plan. Medicaid may cover GLP-1s for obesity at each state's option; KFF counts 13 states doing so as of January 2026. For diabetes, coverage of Mounjaro through Medicaid and Medicare Part D is more common but still plan-specific. ## What actually drives your cost Strip away the noise and five things set your number: which product you are prescribed, because the label drives coverage; whether your plan covers it for your diagnosis; which program you qualify for, since the $25 card and the $50 Bridge copay both have eligibility walls; your dose, because Zepbound self-pay vial pricing steps up as you titrate from 2.5 mg toward a maintenance dose; and where you fill, since retail cash prices for the same box vary by hundreds of dollars between pharmacies. When you budget, use the price of your likely maintenance dose, not the starting dose, and confirm what happens to your price if coverage or a program changes mid-year. ## Where REMEVi fits REMEVi is built for the person who read all of the above and wants off the formulary roller coaster. The price is transparent and flat every month, with no insurance approval to wait on and no surprise at the counter. A licensed physician-led team reviews your health history and determines eligibility before anything is prescribed, medications ship from verified US pharmacies, and a care coordinator stays with you through the early weeks when dose questions actually come up. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. See exactly how [REMEVi's transparent pricing](/pricing/) works, with the numbers stated up front. ## The bottom line As of July 2026, brand tirzepatide lists at about $1,080 to $1,086 a month, retail cash prices run $1,000 to $1,200 or more, Zepbound self-pay vials bring the brand down to roughly $299 to $449 a month depending on dose, a savings card can mean $25 a month for the well-insured, and the new Medicare GLP-1 Bridge puts eligible Part D enrollees at a $50 copay through 2027. The lowest-looking number is not automatically your number; the one that matters is the one attached to your diagnosis, your plan, and your maintenance dose. Compare the parallel breakdown for semaglutide in [how much Ozempic costs](/blog/how-much-does-ozempic-cost/) if you are weighing both molecules. If you would rather have a clinician walk you through the options than decode formularies alone, that is what we are here for. **Your Health. Your Terms.** Real doctors. Real care. [remevihealth.com](/pricing/) --- *This article is for general information and does not constitute medical advice. GLP-1 medications are FDA-approved for specific indications, and eligibility is determined by a licensed clinician. Compounded tirzepatide is a non-FDA-approved preparation prepared by a state-licensed US compounding pharmacy under an individual prescription from a licensed provider. It is not a generic version of, and is not the same as, Mounjaro® or Zepbound®. Compounded preparations have not been clinically studied as finished products. Prices cited are as of July 2026, come from the named sources, and are subject to change without notice. Consult a licensed provider before starting any prescription treatment.*